BG108585A - Използване на atazanavir при лечение на hiv - Google Patents

Използване на atazanavir при лечение на hiv Download PDF

Info

Publication number
BG108585A
BG108585A BG108585A BG10858504A BG108585A BG 108585 A BG108585 A BG 108585A BG 108585 A BG108585 A BG 108585A BG 10858504 A BG10858504 A BG 10858504A BG 108585 A BG108585 A BG 108585A
Authority
BG
Bulgaria
Prior art keywords
hiv
atazanavir
ldl
cholesterol
hiv protease
Prior art date
Application number
BG108585A
Other languages
Bulgarian (bg)
English (en)
Inventor
Clifford Bechtold
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BG108585A publication Critical patent/BG108585A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
BG108585A 2001-08-31 2004-02-17 Използване на atazanavir при лечение на hiv BG108585A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31674501P 2001-08-31 2001-08-31

Publications (1)

Publication Number Publication Date
BG108585A true BG108585A (bg) 2005-04-30

Family

ID=23230468

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108585A BG108585A (bg) 2001-08-31 2004-02-17 Използване на atazanavir при лечение на hiv

Country Status (28)

Country Link
US (1) US20030045501A1 (xx)
EP (1) EP1420799B1 (xx)
JP (1) JP2005501880A (xx)
KR (1) KR20040029447A (xx)
CN (1) CN1245988C (xx)
AT (1) ATE341332T1 (xx)
AU (1) AU2002332610B2 (xx)
BG (1) BG108585A (xx)
BR (1) BR0211544A (xx)
CA (1) CA2458807A1 (xx)
CZ (1) CZ2004288A3 (xx)
DE (1) DE60215189T2 (xx)
DK (1) DK1420799T3 (xx)
EE (1) EE200400065A (xx)
ES (1) ES2274119T3 (xx)
HK (1) HK1061640A1 (xx)
HR (1) HRP20040181A2 (xx)
HU (1) HUP0401091A2 (xx)
IL (1) IL159849A0 (xx)
IS (1) IS7158A (xx)
MX (1) MXPA04001721A (xx)
NO (1) NO20040803L (xx)
NZ (1) NZ530722A (xx)
PL (1) PL367873A1 (xx)
RU (1) RU2316341C2 (xx)
WO (1) WO2003020206A2 (xx)
YU (1) YU12204A (xx)
ZA (1) ZA200401412B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2543596A1 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
US20050148523A1 (en) * 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
KR101185899B1 (ko) 2007-06-12 2012-09-27 콘서트 파마슈티컬즈, 인크. 아자펩티드 유도체
EP2178513B1 (en) * 2007-06-22 2011-03-30 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
WO2009002823A2 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
US20100183715A1 (en) * 2007-06-22 2010-07-22 Bristo-Meyers Squibb Company Tableted compositions containing atazanavir
ATE500820T1 (de) * 2007-06-22 2011-03-15 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
EP2214668A1 (en) * 2007-10-29 2010-08-11 Cipla Limited Novel antiretroviral combination
CN101249138B (zh) * 2008-03-28 2012-03-21 中国人民解放军军事医学科学院野战输血研究所 一种含五味子乙醇提取物的抗艾滋病药物组合物
US20130023496A1 (en) * 2010-04-02 2013-01-24 Randy Tressler Combination Therapy Comprising A CCR5 Antagonist, A HIV-1 Protease Inhibtior and a Pharmacokinetic Enhancer

Also Published As

Publication number Publication date
JP2005501880A (ja) 2005-01-20
IL159849A0 (en) 2004-06-20
HUP0401091A2 (hu) 2004-08-30
HK1061640A1 (en) 2004-09-30
AU2002332610B2 (en) 2007-11-08
CZ2004288A3 (cs) 2004-12-15
US20030045501A1 (en) 2003-03-06
YU12204A (sh) 2006-08-17
BR0211544A (pt) 2004-07-13
KR20040029447A (ko) 2004-04-06
CN1547476A (zh) 2004-11-17
EP1420799B1 (en) 2006-10-04
DK1420799T3 (da) 2007-01-15
NO20040803L (no) 2004-02-24
DE60215189T2 (de) 2007-10-25
EP1420799A4 (en) 2004-11-24
HRP20040181A2 (en) 2004-08-31
ATE341332T1 (de) 2006-10-15
EE200400065A (et) 2004-06-15
NZ530722A (en) 2007-11-30
DE60215189D1 (de) 2006-11-16
WO2003020206A3 (en) 2003-10-02
IS7158A (is) 2004-02-19
RU2316341C2 (ru) 2008-02-10
ZA200401412B (en) 2005-03-18
ES2274119T3 (es) 2007-05-16
WO2003020206A2 (en) 2003-03-13
EP1420799A2 (en) 2004-05-26
CN1245988C (zh) 2006-03-22
MXPA04001721A (es) 2004-05-31
PL367873A1 (en) 2005-03-07
CA2458807A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
Savarino et al. The anti-HIV-1 activity of chloroquine
Klimke et al. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection
Hughes et al. Protease inhibitors for patients with HIV-1 infection: a comparative overview
HUE026849T2 (en) Therapeutic combination containing dolutegravir, abacavir and lamivudine
WO2016036759A1 (en) Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
KR20080081358A (ko) Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
JP2019504857A (ja) Ｈｉｖおよびエイズの治療および予防方法
KR20050044587A (ko) Ｂ형 간염 바이러스 감염 치료용 포스포네이트뉴클레오타이드 유사체의 용도
AU2002332610B2 (en) Use of atazanavir in HIV therapy
D'Abbraccio et al. Efficacy and tolerability of integrase inhibitors in antiretroviral-naive patients.
Nelson et al. Emtricitabine (FTC) for the treatment of HIV infection
AU2002332610A1 (en) Use of atazanavir in HIV therapy
WO2004054586A1 (en) Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
Jain et al. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19: A review
US9463194B2 (en) Methods of treating patients co-infected with HIV and tuberculosis
Fuster et al. Review of atazanavir: a novel HIV protease inhibitor
RU2203047C2 (ru) Композиция для снижения содержания церамидов
Merry et al. Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients
Liao et al. Authentic HIV-1 integrase inhibitors for the treatment of HIV-1/AIDS
Kahn The clinical use of didanosine
Khoo et al. Available Agents: Contraindications and Potential Drug–Drug Interactions
Vizcarra et al. Short communication Efficacy and safety of dolutegravir plus boosted‑darunavir dual therapy among highly treatment‑experienced patients
Blas-García et al. Future perspectives in NNRTI-based therapy: bases for understanding their toxicity
CN116322688A (zh) 用于治疗疟疾的固定剂量的联合用药
Rampling et al. Clinical utility and long-term use of atazanavir in the treatment of HiV-1 infection